drugset / Trial / NCT05538247
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RandomizedParallel-groupDouble-blindBasic science
Summary
This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
Timeline
- Start
- 2023-04-13
- Primary completion
- 2025-12-30
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Indomethacin | Small molecule | 50 mg | Oral |
Indications
No indication recorded.